Supplier News: Olon, Dalton Pharma & Delpharm
The latest news from CDMOs/CMOs and suppliers featuring Olon, Dalton Pharma Services, and Delpharm. Highlights below.
Chemicals/Chemical API Manufacturing
* Olon Completes HPAPI Pilot-Plant Expansion; Forms Solid-State Chemistry Pact
Formulation Development/Drug Product Manufacturing
* Dalton Expands Sterile Mfg Capacity
* Delpharm To Acquire Infusion Bag Company, Carelide
Chemicals/Chemical API Manufacturing
Olon Completes HPAPI Pilot-Plant Expansion; Forms Solid-State Chemistry Pact
Olon, a CDMO of active pharmaceutical ingredients (APIs) and intermediates, has completed the investment in its facility in Rodano, Italy, to expand pilot-plant capacity for scaling up high-potency APIs (HPAPIs) up to a level of containment of OEB5 (1-0.1 ug/m3).
Olon is supported by other pilot plants in its network for the development of HPAPIs, such as its site in Segrate, Italy, with which the Rodano plant will be integrated for increased capacity and improved flexibility.
In a separate development, Olon and the Politecnico di Milano, Department of Chemistry, Materials and Chemical Engineering, have formed a joint public–private partnership for a research project on the advanced study of polymorphism and the characterization of the solid state of the molecules of active ingredients. The three-year project involves a PhD program dedicated to the development of new knowledge on the polymorphism of active ingredients and to the advancement of methods for characterizing the solid state of their molecules.
The PhD will be undertaken by the researcher, Ajay Suresh with the Indian Institute of Science Education and Research, Bhopal, India, who will spend the next few years in Italy working on the project and collaborating in synergy with Olon and the Department of Chemistry at the Politecnico di Milano, under the coordination of Professor Pierangelo Metrangolo, Department of Chemistry, Materials and Chemical Engineering, and President of the Physical and Biophysical Chemistry Division at the International Union of Pure and Applied Chemistry (IUPAC Div. I).
Source: Olon (pilot-plant expansion) and Olon (solid-state chemistry pact)
Formulation Development/Drug Product Manufacturing
Dalton Expands Sterile Mfg Capacity
Dalton Pharma Services, a CDMO of active pharmaceutical ingredients (APIs) and drug products, has announced a strategic expansion of its sterile filling and pharmaceutical manufacturing capacity. The capital expansion plan includes a new cGMP sterile filling line with the flexibility to fill vials, syringes, and cartridges under isolator technology. The sterile fill line is integrated with a new cGMP lyophilizer.
The new filing line is designed to support small-scale commercial manufacturing. The company’s capital expansion plan also includes: (1) additional cGMP non-sterile powder filling capacity; (2) expanded multi-kilogram API capabilities; and (3) greater organic solvent handling and storage infrastructure.
Source: Dalton Pharma Services
Delpharm To Acquire Infusion Bag Company, Carelide
Delpharm, a CDMO of drug products, has partnered with Laboratoire Aguettant, a Lyon, France-based bio/pharmaceutical company, to take over the activities of Carelide, a Mouvaux, France manufacturer of infusion bags.
The Court of Lille Métropole ordered the sale of Carelide’s activities to Delpharm and Laboratoire Aguettant under the terms of their joint bid submitted to the court. The Delpharm / Aguettant offer received the unanimous support of the staff representatives. Under the terms of the offer, Laboratoire Aguettant will take over Carelide’s commercial activities both in France and abroad. Delpharm will take over the industrial activities of Carelide’s Mouvaux manufacturing site. The companies will take over 390 of the 399 employees at the site, and the contracts of approximately 100 temporary workers will be continued.
Carelide is a manufacturer of infusion bags used in hospitals and sold in pharmacies. It produced more than 40 million bags last year (2022). Delpharm and Laboratoire Aguettant plan to modernize the Mouvaux site and increase its manufacturing capacity. Overall, the companies are investing more than EUR 40 milion ($42 million) for the site, which includes EUR 25 million ($26 million) in funding from the French government.
Source: Delpharm
